RNA interference targeting Fas protects mice from fulminant hepatitis

Nature Medicine

Volumn 9, Issue 3, 2003, Pages 347-351

  Song, Erwei ^a,b   Lee, Sang Kyung ^a   Wang, Jie ^b   Ince, Nedim ^a   Ouyang, Nengtai ^c   Min, Jun ^b   Chen, Jisheng ^b   Shankar, Premlata ^a   Lieberman, Judy ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c Guangzhou Medical University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CONCANAVALIN A; FAS ANTIGEN; FAS LIGAND; RNA;

ACUTE HEPATITIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNE HEPATITIS; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HEPATITIS; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; CONCANAVALIN A; DISEASE MODELS, ANIMAL; GENE SILENCING; HEPATITIS, AUTOIMMUNE; HEPATOCYTES; IN SITU NICK-END LABELING; LIVER; MALE; MICE; NECROSIS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

ANIMALIA;

EID: 0037348329     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm828     Document Type: Article

References (30)

1. Hannon, G.J. RNA interference. Nature 418, 244-251 (2002).
2. Rust, C. & Gores, G.J. Apoptosis and liver disease. Am. J. Med. 108, 567-574 (2000).
3. Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
4. Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98, 9742-9747 (2001).
5. McCaffrey, A.P. et al. RNA interference in adult mice. Nature 418, 38-39 (2002).
6. Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A. & Herweijer, H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107-108 (2002).
7. Xia, H., Mao, Q., Paulson, H.L. & Davidson, B.L. siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006-1010 (2002).
8. Kondo, T., Suda, T., Fukuyama, H., Adachi, M. & Nagata, S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3, 409-413 (1997).
9. Siegel, R.M. & Fleisher, T.A. The role of Fas and related death receptors in autoimmune and other disease states. J. Allergy Clin. Immunol. 103, 729-738 (1999).
10. Ogasawara, J. et al. Lethal effect of the anti-Fas antibody in mice. Nature 364, 806-809 (1993).
11. Li, X.K. et al. Fulminant hepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers. Transplantation 71, 503-508 (2001).
12. Canbay, A. et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 123, 1323-1330 (2002).
13. Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735-1737 (1999).
14. Zhang, H. et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat. Biotechnol. 18, 862-867 (2000).
15. Bertrand, J. et al. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 296, 1000-1004 (2002).
16. Schwarz, D.S., Hutvagner, G., Haley, B. & Zamore, P.D. Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 10, 537-548 (2002).
17. Ketting, R.F. et al. Dicer functions in RNA interference and in synthesis of small RNA involved in developmental timing in C. elegans. Genes Dev. 15, 2654-2659 (2001).
18. Lipardi, C., Wei, Q. & Paterson, B.M. RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell 107, 297-307 (2001).
19. Takahashi, T. et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76, 969-976 (1994).
20. Ryo, K. et al. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am. J. Gastroenterol. 95, 2047-2055. (2000).
21. Faouzi, S. et al. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-κB-independent, caspase-3-dependent pathway. J. Biol. Chem. 276, 49077-49082 (2001).
22. Seino, K. et al. Contribution of Fas ligand to T cell-mediated hepatic injury in mice. Gastroenterology 113, 1315-1322 (1997).
23. Takeda, K. et al. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. USA 97, 5498-5503 (2000).
24. Miyazawa, Y., Tsutsui, H., Mizuhara, H., Fujiwara, H. & Kaneda, K. Involvement of intrasinusoldal hemostasis in the development of concanavalin A-induced hepatic injury in mice. Hepatology 27, 497-506 (1998).
25. Galle, P.R. et al. Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J. Exp. Med. 182, 1223-1230 (1995).
26. Takahashi, S. & Lee, M.J. Collagen metabolism in fibrotic liver. Effects of concanavalin A and aggregated myeloma immunoglobin G. Biochem. J. 241, 49-54 (1987).
27. Badawy, A.A. et al. Evaluation of colchicine with or without praziquantel therapy in the control of hepatic fibrosis in murine schistosomiasis. Pharmacol. Res. 33, 319-325 (1996).
28. Dhiman, R.K., Seth, A.K., Jain, S., Chawla, Y.K. & Dilawari, I.B. Prognostic evaluation of early indicators in fulminant hepatic failure by multivariate analysis. Dig. Dis. Sci. 43, 1311-1316 (1998).
29. Klauning, J.E. et al. Mouse liver cell culture. 1. Hepatocyte isolation. In Vitro 17, 913-925 (1981).
30. Kimura, K. et al. Immunopathogenesis of hepatic fibrosis in chronic liver injury induced by repeatedly administered concanavalin A. Int. Immunol. 11, 1491-1500 (1999).